ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018
Anaplastic Lymphoma Kinase Mutation (
Open access · bronzeAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Circulating Tumor DNA as a Biomarker for Precision Medicine in Prostate Cancer: A Systematic Review.International journal of molecular sciences · 2025Pooled it
- Endocrine cancer organoids in basic and translational medical research.Science China. Life sciences · 2025Review
- Tumor organoid-immune co-culture models: exploring a new perspective of tumor immunity.Cell death discovery · 2025Review
- Whole-Exome Sequencing Reveals Novel Candidate Driver Mutations and Potential Druggable Mutations in Patients with High-Risk Neuroblastoma.Journal of personalized medicine · 2024Article
- Exploring potential therapeutic combinations for castration-sensitive prostate cancer using supercomputers: a proof of concept study.Scientific reports · 2024Article
- Article
- Organoids: An Emerging Precision Medicine Model for Prostate Cancer Research.International journal of molecular sciences · 2024Review
- ALK fusions in the pan-cancer setting: another tumor-agnostic target?NPJ precision oncology · 2023Review
- Emerging Role of YAP and the Hippo Pathway in Prostate Cancer.Biomedicines · 2022Review
- Inflammatory bowel disease induces inflammatory and pre-neoplastic changes in the prostate.Prostate cancer and prostatic diseases · 2022Article
- Interplay of Developmental Hippo-Notch Signaling Pathways with the DNA Damage Response in Prostate Cancer.Cells · 2022Review
- miR-106b as an emerging therapeutic target in cancer.Genes & diseases · 2022Review
- Comprehensive assessment of anaplastic lymphoma kinase in localized and metastatic prostate cancer reveals targetable alterations.Cancer research communications · 2022Article
- Small-cell carcinoma of the prostate with negative CD56, NSE, Syn, and CgA indicators: A case report.World journal of clinical cases · 2022Article
- Correction: Inflammatory bowel disease induces inflammatory and preneoplastic changes in the prostate.Prostate cancer and prostatic diseases · 2022Article
- Non-GCB Diffuse Large B-Cell Lymphoma With an Atypical Disease Course: A Case Report and Clinical Exome Analysis.World journal of oncology · 2022Article
- Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma.Cancer research · 2022Article
- Targeting Oncogenic Transcriptional Networks in Neuroblastoma: From N-Myc to Epigenetic Drugs.International journal of molecular sciences · 2021Review
- Knockdown of microRNA-214-3p Promotes Tumor Growth and Epithelial-Mesenchymal Transition in Prostate Cancer.Cancers · 2021Article
- Defining Pathological Activities of ALK in Neuroblastoma, a Neural Crest-Derived Cancer.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 7 institutions in 1 country.
Benedito A Carneiro *Division of Hematology/Oncology, Lifespan Cancer Institute, the Warren Alpert Medical School, Brown University, Providence, Rhode Island. Benedito.carneiro@lifespan.org.
Sahithi Pamarthy *The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois.ORCID 0000-0003-2692-4829
Ami N ShahDevelopmental Therapeutics Program, Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
Vinay SagarThe Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois.ORCID 0000-0003-1717-742X
Kenji UnnoThe Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
HuiYing HanThe Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Ximing J YangDepartment of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Rubens B CostaDevelopmental Therapeutics Program, Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.ORCID 0000-0002-3492-4397
Rebecca J NagyGuardant Health, Inc., Redwood City, California.
Richard B LanmanGuardant Health, Inc., Redwood City, California.ORCID 0000-0001-8122-4329
Timothy M KuzelRush University Medical Center, Division of Hematology/Oncology, Chicago, Illinois.
Jeffrey S RossFoundation Medicine Inc., Cambridge, Massachusetts.
Laurie GayFoundation Medicine Inc., Cambridge, Massachusetts.
Julia A ElvinFoundation Medicine Inc., Cambridge, Massachusetts.
Siraj M AliFoundation Medicine Inc., Cambridge, Massachusetts.
Massimo CristofanilliThe Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Young K ChaeThe Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Francis J GilesDevelopmental Therapeutics Consortium, Chicago, Illinois.ORCID 0000-0002-6919-0231
Sarki A AbdulkadirThe Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Northwestern University · USGuardant (United States) · USBrown University · USMolecular Biology Consortium · USRobert H. Lurie Comprehensive Cancer Center of Northwestern UniversitySUNY Upstate Medical University · USUniversity of Chicago Medical Center · US
Funding
Targeting FOXA1-downstream pathways: a novel therapeutic strategy for castration-resistant prostate cancerP50CA180995 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI ABDULKADIR, SARKI A., HUSSAIN, MAHA H · 2015 to 2025
$19.9MRole of Oncogenic Kinase Pim-1 in Prostate CancerR01CA123484 · NCI · VANDERBILT UNIVERSITY · PI ABDULKADIR, SARKI A. · 2007 to 2017
$2.9MProstate Cancer Recurrence: models and mechanismsR01CA167966 · NCI · VANDERBILT UNIVERSITY · PI ABDULKADIR, SARKI A. · 2012 to 2016
$1.8MNCI NIH HHS P50 CA180995NCI NIH HHS R01 CA123484NCI NIH HHS R01 CA167966
Abstract
PubMed holds no abstract for this paper.
Indexed as
MutationAdultAnaplastic Lymphoma KinaseBiomarkers, TumorCarbazolesCarcinoma, Small CellCell Line, TumorGene Expression ProfilingHigh-Throughput Nucleotide SequencingHumansImmunohistochemistryKaplan-Meier EstimateLiquid BiopsyMaleNeoplasm GradingNeoplasm MetastasisalectinibAnaplastic Lymphoma KinaseBiomarkers, TumorCarbazolesPiperidinesProtein Kinase Inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.